Protocol for the “Implementation, adoption, and utility of family history in diverse care settings” study by R. Ryanne Wu et al.
STUDY PROTOCOL Open Access
Protocol for the “Implementation, adoption,
and utility of family history in diverse care
settings” study
R. Ryanne Wu1*, Rachel A. Myers2, Catherine A. McCarty3, David Dimmock4, Michael Farrell5, Deanna Cross6,
Troy D. Chinevere7, Geoffrey S. Ginsburg8, and Lori A. Orlando9 for the Family Health History Network
Abstract
Background: Risk assessment with a thorough family health history is recommended by numerous organizations
and is now a required component of the annual physical for Medicare beneficiaries under the Affordable Care Act.
However, there are several barriers to incorporating robust risk assessments into routine care. MeTree, a web-based
patient-facing health risk assessment tool, was developed with the aim of overcoming these barriers. In order to
better understand what factors will be instrumental for broader adoption of risk assessment programs like MeTree
in clinical settings, we obtained funding to perform a type III hybrid implementation-effectiveness study in primary
care clinics at five diverse healthcare systems. Here, we describe the study’s protocol.
Methods/design: MeTree collects personal medical information and a three-generation family health history
from patients on 98 conditions. Using algorithms built entirely from current clinical guidelines, it provides
clinical decision support to providers and patients on 30 conditions. All adult patients with an upcoming
well-visit appointment at one of the 20 intervention clinics are eligible to participate. Patient-oriented risk
reports are provided in real time. Provider-oriented risk reports are uploaded to the electronic medical record
for review at the time of the appointment. Implementation outcomes are enrollment rate of clinics, providers,
and patients (enrolled vs approached) and their representativeness compared to the underlying population.
Primary effectiveness outcomes are the percent of participants newly identified as being at increased risk for
one of the clinical decision support conditions and the percent with appropriate risk-based screening.
Secondary outcomes include percent change in those meeting goals for a healthy lifestyle (diet, exercise, and
smoking). Outcomes are measured through electronic medical record data abstraction, patient surveys, and
surveys/qualitative interviews of clinical staff.
Discussion: This study evaluates factors that are critical to successful implementation of a web-based risk
assessment tool into routine clinical care in a variety of healthcare settings. The result will identify resource
needs and potential barriers and solutions to implementation in each setting as well as an understanding
potential effectiveness.
Trial registration: NCT01956773
Keywords: Risk stratification, Prevention, Primary care, Family health history
* Correspondence: ryanne.wu@duke.edu
1Duke Center for Applied Genomics & Precision Medicine and Duke
Department of Medicine, Duke University, 411 West Chapel Hill Street, Ste.
500, Durham, NC 27705, USA
Full list of author information is available at the end of the article
Implementation
Science
© 2015 Wu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wu et al. Implementation Science  (2015) 10:163 
DOI 10.1186/s13012-015-0352-8
Background
Failure to assess risk for common chronic diseases
before they develop increases the likelihood that primary
care patients will be faced with premature morbidity and
mortality. Risk assessments integrate data from multiple
sources including laboratory, biometric, genetic, envir-
onmental, and behavioral. Though the type of data
synthesized for any one disease depends upon the risk
algorithm, many rely heavily upon a detailed family
health history (FHH), and in some cases such as Lynch
syndrome, hemochromatosis, cystic fibrosis, and heredi-
tary arrhythmias, FHH is the only data source [1–6].
Morbidity and mortality reductions are achieved by
linking risk assessment results to evidence-based risk
management guidelines which can both improve out-
comes and more efficiently allocate medical resources in
comparison to “one size fits all” medicine by, for
example, encouraging appropriate timing and frequency
of colorectal cancer surveillance [7], appropriate timing
and method of breast cancer surveillance [8–10], breast
cancer chemoprevention [11, 12], and cancer genetic
counseling [13–16]. Given these benefits, risk assess-
ment with a thorough FHH is recommended by numer-
ous medical organizations, including the Centers for
Disease Control and Prevention [17], U.S. Office of the
Surgeon General [18], American Heart Association [4],
and American Society of Clinical Oncology [1].
Implementing FHH-based risk assessment and man-
agement guidelines into practice is hindered by system-,
clinician-, and patient-level barriers. System barriers in-
clude limited time available to record a thorough FHH
[19–22] and lack of data standardization. Clinician
barriers include limited awareness of the necessary data
elements for risk stratification (e.g., age of onset) and
limited training in how to synthesize FHH data into a
risk management plan [23–26]. Patient barriers include
limited knowledge about their FHH, the essential ele-
ments of FHH to provide, and the benefits of risk
management [17, 24]. Health IT tools that collect
patient-entered FHH and provide risk-based clinical
decision support (CDS) have overcome some of these
barriers. Evaluation of these tools has shown that they
improve collection and documentation of high-quality
FHH in 46–78 % of patient encounters [27–29] without
impeding primary care clinic operations. Further,
these tools have demonstrated the potential for high
clinical utility by successfully identifying individuals
who were either unaware of or not adherent to risk-
based management [28, 30–32] and improving adher-
ence to cancer screening [17, 33] and lifestyle change
recommendations [34, 35].
In 2004, the Genomedical Connection, a collaboration
by Duke University, University of North Carolina at
Greensboro, and Cone Health, developed the genomic
medicine model to help integrate personalized medicine
into North Carolina primary care practices [36]. One key
component of this model was the development and
implementation of MeTree, a web-based patient-facing
FHH-driven risk assessment and clinical decision sup-
port tool with integrated just-in-time education [37].
The initial version of MeTree, which collected data on
48 medical conditions and generated clinical decision
support on five diseases (hereditary cancer syndromes,
breast cancer, ovarian cancer, colon cancer, and throm-
bosis), was successfully piloted in three Cone Health
community-based primary care clinics (two intervention
sites and one control). These results included broad-
based support from both patients and providers for its
ease of use [38], improved identification of increased risk
primary care patients [38, 39], high quality of FHH
collection [40, 41], and increased alignment of patient
care with risk management guidelines (paper in review).
These encouraging results led to grant funding from
NHGRI and NCI as part of the Implementing Genom-
ics in Practice (IGNITE) network (http://www.ignite-
genomics.org) to optimize MeTree and evaluate its
uptake and impact across a variety of diverse real
world settings. Optimization and expansion of MeTree
have been completed and include a tablet friendly user
interface, help text linked to MedlinePlus Connect,
incorporation of American Health Information Com-
munity’s requirements for FHH collection [42], full
HL7 standards compatibility (www.hl7.org), data
linked to ICD-9 and SNOMED codes for interoper-
ability, data collection for 90 conditions, clinical
decision support for 30 conditions (breast cancer,
colon cancer, lung cancer, ovarian cancer, hereditary
cancer syndrome, hereditary cardiovascular diseases,
connective tissue diseases, hereditary liver diseases,
abdominal aortic aneurysm, type 2 diabetes, coronary
artery disease, and ischemic stroke), and the addition of a
Spanish version. In this paper, we describe the pragmatic
cluster controlled implementation-effectiveness hybrid
type III trial designed to evaluate the implementation
uptake and clinical utility of MeTree in five diverse
healthcare systems across the USA.
Methods/design
Models
In order to effectively and efficiently integrate the
FHH intervention into clinical practices, we employed
an implementation sciences approach based upon the
reach, efficacy, adoption, implementation, and mainten-
ance (RE-AIM) model [43] and the Weiner organizational
model of innovation implementation [44]. This approach
is the key to understanding the optimal adaptations
necessary for maximizing the impact of risk assess-
ment programs (here represented by MeTree) across
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a diversity of settings—a critical component for facili-
tating widespread adoption.
The RE-AIM framework assesses an intervention’s
potential to broadly improve population health, and the
likelihood it will be translated into clinical practice. The
model measures the following: Reach (the number,
percent, and representativeness of the eligible interven-
tion population), Effectiveness, Adoption (the number,
percent, and representativeness of the participating
intervention sites), Implementation [the extent of inter-
vention delivery as intended (integrity) and frequency of
use (exposure)], and Maintenance [43].
The adapted Weiner organizational model of innovation
implementation (Fig. 1) builds upon the RE-AIM model
by providing explanatory characteristics for the RE-AIM’s
measures. Within the Weiner model, Implementation
Policies and Practices are organizational strategies for
using an innovation and the actions that follow. Examples
are education and training, recognition and reward,
communication and coordination, and time to experiment
[45]. Implementation Climate is employees’ perception of
the organization’s expectation for innovation use [46].
Innovation-Task Fit is compatibility with task demands,
processes, and organizational capabilities. Innovation-
Values Fit is compatibility with users’ values [46–49].
Implementation Effectiveness is the consistency and quality
of innovation use [46, 50–52]. Innovation Effectiveness is
the organizational benefits that accrue from innovation
use (i.e., improved clinical care) [46, 48].
Overview of study design
This clinical trial includes five national healthcare
systems with distinct missions and operational profiles:
Duke University Medical Center, Medical College of
Wisconsin (MCW), Essentia Institute of Rural Health
(EIRH), University of North Texas (UNT), and David
Grant U.S. Air Force Medical Center. Duke and MCW
are both academic health centers but each enrolled
clinics that represent different populations: highly
educated middle class, inner city, blue collar, and
suburban. The clinics at EIRH represent rural popula-
tions, David Grant military populations, and UNT
migrant Hispanic populations.
To understand the characteristics of each of these set-
tings and how they impact uptake and clinical utility, we
developed a pragmatic cluster hybrid implementation-
effectiveness type III protocol with three phases (Table 1):
pre-implementation assessments, implementation with
strategic adaptations, and post-implementation assess-
ments [53]. Hybrid study designs provide a structure for
the complex process of collecting two entirely different
types of information: implementation (how well the
intervention is taken up by the clinical sites) and effect-
iveness (the clinical impact of the intervention). The
choice between type I, II, or III designs depends upon
the amount of underlying effectiveness data, in the case
of type III studies, the effectiveness data is extensive
enough that implementation is the primary outcome and
effectiveness the secondary outcome [53].
Recruitment, enrollment, and sample size
Primary care clinics within each of the five healthcare
systems represent five states, 20 clinics, 79 providers,
and ~45,500 unique patients per year from a variety of
sociodemographic backgrounds (Table 2). Enrolled clinics
were matched by sociodemographic factors to a represen-
tative clinic to serve as a control for the health system.
Enrollment occurred in a stepped process with an initial
implementation in one to four clinics. After 3–4 months,
the remainder of the clinics began enrolling. The control
clinics will convert to intervention clinics as part of the
delayed roll out and will begin enrolling 1 year after study
start date. Data from the control clinics will be used to
account for temporal trends in clinical care.
Providers
Since provider decision-making is integral to study out-
comes, providers in the participating clinics are enrolled
in the study. Provider-participants are recruited through
in-person clinic meetings and individual email communi-
cation. A clinical champion at each clinic is identified to
help facilitate implementation. Educational modules for
providers were developed, including a website (http://
dukepersonalizedmedicine.org/disease-risk-and-diagnosis/
risk-assessments/family-history), a one-page summary of
benefits and activities, and two webinars.
Fig. 1 Weiner’s organizational model of innovation implementation
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Patients
Patients of enrolled providers who have an upcoming
well-visit appointment and meet inclusion/exclusion
criteria (see below) are sent invitations (via mail or
email) and educational materials 3 weeks prior to their
appointment. Interested participants are enrolled into an
entirely electronic protocol (see below) by a central
coordinator. We anticipate enrolling 3000 patient-
participants at a minimum (to achieve significance for
effectiveness measures), but as an observational study,
we will continue to enroll as many as are interested in
order to maximize our ability to assess differences
across settings, populations, and sociodemographic
factors. To reach this goal, we need to enroll ~157
patient-participants from each intervention clinic.
Assuming a 10 % enrollment rate, we anticipate being
able to enroll 4500 patient-participants.
Patient inclusion/exclusion criteria
Patients must be over the age of 18, English or Spanish
speaking, and have an enrolled provider to be eligible.
Since this proposal focuses upon prevention and not
disease management strategies, those with one of the
CDS study disease (e.g., breast cancer) will not be
excluded from enrollment but will be excluded from
analyses relevant to that disease.
Electronic protocol and participant flow
Interested patients contact the study coordinator, either
by phone or an electronic link embedded in the email
invitation, to create an account in study system. At this
point, the remainder of the study flow is entirely
electronic. When they log-in to their account, they are
emailed a link to an electronic consent. After consenting,
they are emailed a link to complete a web-based baseline
survey (Table 3). Upon completing the survey, they are
emailed a secure link to access MeTree. They may log-in
and out as often as they need to complete data entry. The
patient-participant is required to complete MeTree 2 days
prior to their appointment in order to upload the provider
report to the medical record. At 3 and 12 months post-
appointment, patients are sent an electronic survey to
complete. In addition, an EMR data query for measures
relevant to risk management and results will be performed
at 12 months (Fig. 2).
Patient education and support
MeTree incorporates embedded FHH education on why
FHH is important for their health, how to use the
program, how to collect FHH from family members, what
to ask about, and what information to gather about their
own health history. A downloadable worksheet facilitates
data collection of the key FHH components. Participants
will collect and enter their own personal information and
FHH into MeTree from a personal computer, mobile
device, or a dedicated clinic kiosk. Within MeTree .api
links to MedlinePlus Connect allow the display of low
literacy content for a disease when the cursor hovers over
the name. Participants are given a support email address
and phone number to contact for assistance if needed.
Delivery of results
Once patient-participants complete MeTree, the patient
report is available in real time to print or save. A
Table 1 Hybrid implementation-effectiveness design elementsa
Pre-implementation Implementation Post-implementation
• Identify current practice patterns • Assess implementation integrity (used as intended) • Assess acceptance and satisfaction for stakeholders
• Identify barriers and facilitators • Assess implementation exposure (used at intervention sites) • Assess clinical impact for all stakeholders
• Assess feasibility • Identify explanations and solutions for low integrity or intensity • Adapt and finalize implementation strategy
• Establish implementation plan • Modify implementation plan • Assess impact of final implementation strategy
aAdapted from [64]
Table 2 Clinical site demographics
Duke MCW Essentia UNT Air force
State(s) NC WI MN, WI, ND, ID TX CA
Setting Academic Urban Rural Migrant Military
Female 61 % 51 % 54 % 61 % 19 %
Caucasian 59 % 77 % 99 % 46 % 73 %
Medicare/medicaid 27 % NA 26 % 70 % 0 %
Uninsured 6 % NA 8 % 1 % 0 N
Enrolled clinics 7 5 2 3 3
Waitlisted clinics 1 1 6 2 1
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Table 3 Domains of patient- and physician-oriented outcomes by data source
Data source
MeTree Patient surveys Provider survey Clinic staff survey (ORIC) Clinic staff interview EHR data pull
Emotional
Satisfaction ● ● ● ●
Barriers to model use ● ●
Activation ●
Quality of clinical encounter ● ●
SF-12 (quality of life) ●
Patient activation ●
Knowledge ●
Concur with/quality of CDS ●
ORIC ●




Rec uptake ● ● ●
Discussion of risk/prevention ●
Work flow/processes ●
Implementation policies/practices ● ●




FHH documentation/ counseling ●
% completion of MeTree ●
Time to complete MeTree ●
Clinical
Laboratory data ● ●
Screening completed ●
Complications ●
Vital signs and weight ● ●
# medications ●
Referrals made ●
% high-risk patients ●
% with risk-based screening ● ●
% with screening completed ●
% with disease at goal ●





Impact on family members ●
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provider report including disease-oriented CDS based
on current clinical guidelines (e.g., USPSTF, NCCN), a
pedigree, and a tabular FHH is simultaneously generated
and uploaded to the (E)MR. The provider-participant is
then alerted to report availability. At the appointment,
the clinical encounter proceeds as usual (Fig. 2).
Study phases
Pre-implementation
Assessments during the pre-implementation phase were
based on the adapted Weiner organizational model of
innovation implementation. Mixed methods were used
to assess characteristics related to the organizational
environment, providers, and the patient population
being served, in addition to perceived barriers/facilita-
tors, potential adaptations, pros/cons of each interven-
tion aspect (FHH collection, education, CDS output,
CDS delivery, model integration, etc.), IT use, and
comfort with FHH risk stratification (Table 1). A repre-
sentative sampling of providers and staff was interviewed
over the phone by a dedicated interviewer using a separate
question guide for each position (nursing, clerk, provider,
etc.). All providers and staff members at enrolled clinics
were also invited to complete the organizational readiness
for implementing change (ORIC), a validated survey
instrument based on Weiner’s model [54].
Implementation and post-implementation
During implementation, progress-focused formative
evaluations and summative quantitative measures assess
characteristics related to implementation (implemen-
tation effectiveness, innovation effectiveness, sustaina-
bility/maintenance). Results are used to understand
barriers arising during implementation, adapt the imple-
mentation to overcome those barriers, and identify
critical elements required for the success of the risk
assessment intervention in each environment. Providers
and clinic staff are interviewed informally in an ongoing
manner throughout the study and formally at 6 months
post-enrollment. Providers are interviewed about satis-
faction, unexpected barriers, impact on clinic processes
and appointment quality, whether CDS was helpful in
decision making, how patients reacted, and what would
be necessary to establish the intervention as part of their
Fig. 2 Study flow
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routine clinical care. Nurses are interviewed about
impact on workflow, patient questions, and how their
role in the clinic may have changed.
Study measures and outcomes
Quantitative data are obtained in three areas: (1) surveys
of provider- and patient-participants around the uptake
and acceptance of the intervention; (2) clinical effective-
ness measures; and (3) patient-centered measures related
to the clinical, behavioral, and emotional domains.
Given the natural tension between implementation
measures, which require considerable input from partici-
pants, and pragmatic trials, which assume a hands-off
observational intervention, we have devised measures
across domains and stakeholders that meet both goals.
Note that since the length of the study limits the ability to
assess hard clinical outcomes such as reduction in cardiac
events or incident cancer, we will use Healthcare Effective-
ness Data and Information Set measures as intermediate
clinical effectiveness measures for the CDS conditions.
Measures are presented in Tables 3 and 4. Implementation
outcomes are clinic, provider and patient adoption (enroll-
ment rates), and representativeness to the underlying
population. Primary effectiveness outcomes are percent
newly identified high-risk individuals and percent with
appropriate risk-based screening. Secondary outcomes
include percent change in those meeting goals for a
healthy lifestyle (diet, exercise, and smoking).
Data analysis
Sample size calculations were preformed analytically
using R. For each of the five behavior changes of inter-
est, the baseline rates were obtained from the CDC’s
Behavioral Risk Factor Surveillance Data [55] and are as
follows: breast cancer screening—70 %, colon cancer
screening—55 %, smoking—43 %, healthy diet—24 %,
and controlled LDL—78 %. We analytically determined
the number of patients required to detect a 5, 6, 7, 8, 9,
and 10 % increase or decrease from the baseline rates in
a one-sample test of proportions with a significance level
of 0.05 and 80 % power. To account for within-clinic
correlations in patient behavior, we estimated the
variance inflation factor (VIF) assuming an intraclass
correlation of 15 % [cite PMID: 22585888] with 20
intervention clinics for each behavior of interest. After
accounting for the within-clinic correlation, 20 % attri-
tion, a ~3:1 female to male ratio, and multiple be-
haviors/comparisons, approximately 2000 patients are
needed to detect 10 % changes and 20,000 are needed
to detect 5 % changes.
Pre-implementation and Implementation qualitative
and quantitative data from physician and staff inter-
views and surveys will be reviewed by the study PIs and
key personnel for themes to guide the development and
adaptation of the implementation strategy. Particular
attention will be paid to identifying potential barriers
and facilitators that will lead to an implementation plan,
Table 4 RE-AIM implementation outcomes and measures
Outcomes Measure Source
Model reach Representativeness of patient population
to general population
Recruitment data (# enrolling/# invited); SES and
demographics compared to overall population;
compare across clinical settings and institutions
Effectiveness see Domains of Measures and Outcomes Table
Model adoption Representativeness of clinics agreeing to participate Recruitment data on clinic settings and characteristics
as compared to general clinic settings at the
institution; % of providers opting out and their
characteristics compared to overall provider population
in the clinics; formative evaluations on reasons
for opting out
Implementation integrity % time intervention used as intended Formative evaluations, study coordinator tracking
patient through steps in the model (ex. MeTree
log-in vs completion), adaptations to the model,
patient and provider FAQs derived during
implementation, % time providers review
CDS output
Implementation exposure % time intervention used Formative evaluations, study coordinator tracking
patient through steps of the model
Maintenance and sustainability Cost to implement • EHR administrative data for utilization
Cost/effectiveness • Formative evaluations (clinic resource needs,
successful elements for each setting, factors
association with long-term adoption or not),
• % adoption at study end
• costs/disease prevented, early stage detected,
or visits avoided
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which minimizes changes to workflow and staff duties.
Implementation phase data, such as experience with
the model, satisfaction, and impact on clinic workflow
will be analyzed continuously and used to inform
model adaptation until the time when optimization
has occurred. At that point, frequency of provider
data collection and analysis of both the patient and
provider related data will decrease. The final result
will be an “implementation template” for each general
setting.
Effectiveness data will be summarized with descriptive
statistics and plots. Generalized linear ordinal regression
models (GLO) (the function ordglm from the R statistics
package) will fit ordinal survey outcomes to the continu-
ous outcome variables. Associations will be considered
significant when the regression coefficient is not zero; a
false discovery rate of 5 % will be used to correct for
multiple comparisons. Multivariate analysis will control
for clinic and provider. A p value of <0.1 in stepwise
regression will identify significant factors such as demo-
graphics, intent to change, and their interactions. The
analyses for the multiple outcomes will follow the same
procedure as the survey outcomes but using a logistic
regression model that includes the seven covariate
factors (see sample size section). Although the study is
implemented at the level of the clinical practice, the like-
lihood of clustering is low given that all participants
undergo the intervention and the intervention is aimed
at both the patient and the provider; however, to address
the possibility of clustering, we will calculate a design
effect [56]; if it is 1, we will use standard tests and general-
ized linear mixed models with clinic and state as random
effects, if not, we will adjust the confidence intervals using
a conditional logistic regression [57]. Effect size bias is
extremely unlikely in this non-randomized study as all
individuals receive the intervention, preventing the imbal-
ance in treatment assignment that can lead to inaccurate
point estimates [57].
RE-AIM data will be analyzed as in Table 4.
Discussion
Risk stratification is an essential first step in mitigating risk
and improving prevention efforts both on an individual
and a population level. FHH is a critical component of that
risk stratification and the most valuable and comprehen-
sive “genetic test” we have available today. While patients
and clinicians acknowledge the value of risk stratification
and FHH [58, 59], there remain significant barriers to
collection and utilization within clinical practice under
current patterns of care [24, 25, 60, 61]. Development and
use of electronic tools for collection and analysis of risk
information has the potential to address many of these
barriers [27–29] and to improve clinical care [29, 62, 63].
Yet at the same time, introducing technology into the
clinical setting can present its own set of obstacles that
must be evaluated and addressed.
This trial seeks to evaluate both the process of imple-
mentation of a web-based FHH platform into diverse
clinical settings and its clinical effectiveness across
those settings. Implementation outcomes will be mea-
sured using the RE-AIM framework. Patient-, provider-,
system-level barriers and facilitators to implementation
will be assessed through ongoing surveys of all partici-
pants and interviews of representative stakeholders
throughout pre-implementation, implementation, and
post-implementation phases of the study. Maintenance
and sustainability will be measured by development of
a CEA model to assess societal and institutional impact
of such an intervention using prospectively collected
data from the trial when possible. This will allow for
evaluation of the potential impact of MeTree within
different clinical settings and across the US population
as a whole. Clinical effectiveness will be measured
through (E)MR data pulls at the end of the study to
assess provider and patient clinical activity as a result
of the MeTree intervention as well as health behavior
surveys of patient-participants pre- and post-intervention.
While application of technology within healthcare
presents new challenges, it also provides opportunities
to improve the care of patients and their families. This is
particularly true when considering risk assessments which
are best applied systematically with the most up-to-date
and accurate data possible, something that has not been
achievable in current practice. When applied thoughtfully
and methodically, great benefit can be seen for patients
and providers.
Trial status
Providers and patient participants at Duke began enrolling
April 2014, Essentia began enrolling May 2014, MCW
began in October 2014, UNT began in July 2015 and Da-
vid Grant began in October 2015.
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